SGP vs SLGL

SpyGlass Pharma, Inc. vs Sol-Gel Technologies Ltd. — Valuation Comparison 2026

SGP

Biotechnology
SpyGlass Pharma, Inc.
Quality
5.0
out of 10
Value Trap
Price
$19.84
Last close
Models
7/13
Active
VS

SLGL

Biotechnology
Sol-Gel Technologies Ltd.
Quality
2.1
out of 10
Value Trap
Price
$75.28
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType SGP Fair ValueSGP Upside SLGL Fair ValueSLGL Upside
Bayesian DCF Intrinsic $5.82 -70.7% $19.96 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.00 -89.9% $4.09 -94.5%
PWERM Option-Based $12.93 -34.8% $47.09 -36.2%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SGP vs SLGL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SGP vs SLGL — Which Stock Is More Undervalued?

SGP scores higher with a 5.0/10 quality rating vs SLGL's 2.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing SpyGlass Pharma, Inc. (SGP) and Sol-Gel Technologies Ltd. (SLGL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SGP currently trades at $19.84 with a QOC of 5.0/10, while SLGL trades at $75.28 with a QOC of 2.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).